Table I.
Baseline characteristics of the study population.
| Demographic variable | Mean ± S.D. | Range |
|---|---|---|
| Age (years) | 71.56±10.33 | 31–86 |
| Sex (male:female ratio) | 80:23 | |
| Etiology (HBV/HCV/non-HBV, non-HCV) | 18/54/31 | |
| Size (mm) | 25.78±9.76 | 10–60 |
| AFP (ng/ml) | 122.53±396.92 | 1.5–2,578.7 |
| DCP (mAU/ml) | 643.51±2,256.19 | 10.0–14,874.0 |
| Serum albumin (g/dl) | 3.67±0.46 | 2.5–4.7 |
| Prothrombin activity (%) | 96.32±14.73 | 54.9–127.1 |
| Total bilirubin (mg/dl) | 0.67±0.34 | 0.21–2.1 |
| Artificial effusion? (yes/no) | 35:68 | |
| Sonazoid™? (yes/no) | 35:68 | |
| Fusion imaging? (yes/no) | 25:78 | |
| Child-Pugh Score (5/6/7/8) | 67/23/8/5 | |
| Class (A/B) | 90/13 | |
| With/without prior TACE | 76/27 |
HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, α-fetoprotein; DCP, des-gamma-carboxy prothrombin; TACE, transarterial chemoembolization; S.D., standard deviation.